ArticleStereotactic and functional neurosurgery2026
Dopamine Transporter Imaging Predicts Mortality in a Long-Term Follow-Up after Subthalamic Deep Brain Stimulation in Parkinson's Disease.
Article in Stereotactic and functional neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDeep brain stimulation of the subthalamic nucleus (STN-DBS) is an efficient treatment for advanced Parkinson's disease (PD), when oral medication no longer provides satisfactory symptom control or causes disabling side effects. However, long-term outcomes vary considerably, and reliable preoperative biomarkers remain lacking. Dopamine transporter single-photon emission computed tomography (DAT SPECT) provides an indirect in vivo measure of presynaptic striatal dopaminergic degeneration in the basal ganglia. In patients evaluated for STN-DBS, DAT SPECT with [123I]FP-CIT supported the clinical diagnosis. This study aimed to examine whether preoperative DAT SPECT predicts the long-term outcome after STN-DBS surgery.
methodsFifty-five patients with PD underwent DAT SPECT before STN-DBS surgery. Motor symptoms were assessed in ON and OFF medication states before surgery, and at long-term follow-up, 8-14 years after surgery. Cognition was assessed before surgery and at the long-term follow-up, and clinical data were curated retrospectively from medical records.
resultsLower DAT striatal specific binding ratio (SBR) significantly correlated with longer disease duration, indicating greater dopaminergic loss. Reduced striatal SBR predicted increased mortality during the long-term follow-up. Regional analyses revealed that this association was driven by the caudate nucleus. Furthermore, greater caudate compared to putaminal involvement, reflected by a higher putaminal/caudate uptake ratio, was related to longer disease duration and increased mortality. Preoperative DAT SPECT measures were not associated with DBS effect, cognitive function, or depression.
conclusionDopamine transporter imaging provides valuable insight into the pathophysiology and disease progression of PD. Although DAT SPECT did not predict the therapeutic effect of STN-DBS, this study demonstrates that DAT SPECT captures aspects of disease progression and survival in PD. These results highlight the value of assessing the dopaminergic system before advanced treatment, as DAT SPECT may provide prognostic indicators that could complement the preoperative evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.